Guard Therapeutics International AB (publ) (GUARD.ST) Research

Guard Therapeutics International AB (publ) is a Swedish pharmaceutical company dedicated to the research, development, and commercialization of therapeutic solutions for the diagnosis and management of acute kidney injuries. A key offering is ROSGard, a biological drug candidate designed to prevent kidney impairment through the protection, purification, and restoration of affected cells and tissues. Founded in 2008, the company operated as A1M Pharma AB (publ) until its renaming to Guard Therapeutics International AB (publ) in October 2019. Its headquarters are located in Stockholm, Sweden.

Market snapshot

Symbol
GUARD.ST
Price
$1.55
Day change
+2.11%
Market cap
$31.3M
P/E ratio
-0.38x
52-week range
0.881-27
Sector
Healthcare
Industry
Biotechnology
Next earnings
in 2 months

Peer companies

  • 2cureX AB (publ) (2CUREX.ST)
  • Aptahem AB (publ) (APTA.ST)
  • Episurf Medical AB (publ) (EPIS-B.ST)
  • Fluicell AB (publ) (FLUI.ST)
  • Modus Therapeutics Holding AB (publ) (MODTX.ST)
  • ODI Pharma AB (ODI.ST)
  • Prostatype Genomics AB (publ) (PROGEN.ST)
  • Qlife Holding AB (publ) (QLIFE.ST)

Open Guard Therapeutics International AB (publ) (GUARD.ST) in Thesis for live fundamentals, charts, options context, and portfolio-aware Copilot follow-ups.